| [1] |
Martelli MP,Sporeoletti P,Tiacci E, et al.Mutational landscape of AML with normal cytogenetics：biological and clinical implications[J]. Blood Reviews, 2013, 27(1): 13-22.
|
| [2] |
Swerdlow SH,Campo E,Harris NL, et al.WHO classification of tumours of haematopoietic and lymphoid tissues[J].4th ed, Lyon：IARC, 2008.
|
| [3] |
Mardis ER,Ding L,Dooling DJ, et al.Recurring mutations found by sequencing an acute myeloid leukemia genome[J]. N Engl J Med, 2009, 361(11): 1058-1066.
|
| [4] |
Marcucci G,Maharry K,Wu YZ,el al.IDHl and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia：a Cancer and Leukemia Group B study[J]. J Clin Oncol, 2010, 28(14): 2348-2355.
|
| [5] |
Plaut GW,Cook M,Aogaichi T. The subcellular location of Isozymes of NADP-isocitrate dehydrogenase in tissues from pig, ox and rat[J]. Biochim Biophys Acta, 1983, 760(2): 300-308.
|
| [6] |
Geisbrecht BV,Gould SJ.The human PICD gene encodes a cytoplasmic and peroxisomal NADP(＋)-dependent isocitrate dehydrogenase[J]. J Biol Chem, 1999, 274(43): 30527-30533.
|
| [7] |
Oh IU,Inazawa J,Kim YO, et al.Assignment of the human mitochondrial NADP(＋)-specific isocitrate dehydrogenase (IDH2)gene to 15q26.1 by in situ hybridization[J]. Genomics, 1996, 38(1): 104-106.
|
| [8] |
Ward PS,Patel J,Wise DR, et al.The common feature of leukemia associated IDHl and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate[J]. Cancer Cell, 2010, 17(3): 225-234.
|
| [9] |
Figueroa ME,Abdel Wahab O,Lu C, et al.Leukemic IDHl and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation[J]. Cancer Cell, 2010, 18(6): 553-567.
|
| [10] |
Ko M,Huang Y,Jankowska AM, et al.Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2[J]. Nature, 2010, 468(7325): 839-843.
|
| [11] |
Chowdhury R,Yeoh KK,Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases[J]. EMBO Rep, 2011, 12(5): 463-469.
|
| [12] |
Zhao S,Lin Y,Xu W, et a1.Glioma-derived mutations in IDH1 dominantly inhibit IDHI catalytic activity and induce HIF-1alpha[J]. Science, 2009, 324(5924): 261-265.
|
| [13] |
Im AP,Sehgal AR,Carroll MP, et al.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies：associations with prognosis and potential treatment strategies[J]. Leukemia, 2014, 28(9): 1774-1783.
|
| [14] |
王蓉娴,吴德沛,陈苏宁, 等. 急性髓系白血病患者IDHl及IDH2基因突变及临床特征分析[J]. 中华医学杂志, 2013, 93(10): 751-755.
|
| [15] |
贾祝霞,周民,晁红颖, 等. 急性髓系白血病患者IDHl和IDH2基因突变分析[J]. 中华血液学杂志, 2012, 33(5): 397-401.
|
| [16] |
Chao HY,Jia ZX,Chen T, et al .IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype[J]. Int J Lab Hemato, 2012, 34(5): 502-509.
|
| [17] |
Yamaquchi S,Iwanaqa E,Tokunaqa K, et al.IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation[J]. Eur J Haematol, 2014, 92(6): 471-477.
|
| [18] |
Koszarska M,Bors A,Feczko A, et al.Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia[J]. Leuk Lymphoma, 2013, 54(5): 1028-1035.
|
| [19] |
Chotirat S,Thongnoppakhun W,Promsuwicha O, et al.Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients[J]. J Hematol Oncol, 2012(5): 5.
|
| [20] |
Nomdedeu J,Hoyos M,Carricondo M, et al.Adverse impact of IDH1 and IDH2 mutations in primary AML：experience of the Spanish CETLAM group[J]. Leuk Res, 2012, 36(8): 990-997.
|
| [21] |
Chou WC,Hou HA,Chen CY, et al.Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation[J]. Blood, 2010, 115(14): 2749-2754.
|
| [22] |
Patel KP,Ravandi F,Ma D, et al.Acute myeloid leukemia with IDH1 or IDH2 mutation：frequency and clinicopathologic features[J]. Am J Clin Pathol, 2011, 135(1): 35-45.
|
| [23] |
Abbas S,Lugthart S,Kavelaars FG, et al.Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia：prevalence and prognstic value[J]. Blood, 2010, 116(12): 2122-2126.
|
| [24] |
Patel JP,Gonen M,Figueroa ME, et al.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J]. N Engl J Med, 2012, 366(12): 1079-1089.
|
| [25] |
Estey EH.Acute myeloid leukemia：2013 update on risk-stratification and management[J]. Am J Hematol, 2013, 88(4): 318-327.
|
| [26] |
Chou WC,Lei WC,Ko BS, et al.The prognostic impact and stability of lsocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia[J]. Leukemia, 2011, 25(2): 246-253.
|
| [27] |
Paschka P,Schlenk RF,Gaidzik VI, et al.IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FL T3 internal tandem duplication[J]. Journal of clinical oncology, 2010, 28(22): 3636-3643.
|
| [28] |
Ravandi F,Patel K,Luthra R, et al.Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin[J]. Cancer, 2012, 118(10): 2665-2673.
|
| [29] |
Dinardo CD,Propert KJ,Loren AW, et al.Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia[J]. Blood, 2013, 121(24): 4917-4924.
|
| [30] |
Fathi AT,Sadrzadeh H,Borger DR, et al.Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response[J]. Blood, 2012, 120(23): 4649-4652.
|
| [31] |
Dinardo CD,Patel KP,Garcia-Manero G, et al.Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents[J]. Leuk Lmphoma, 2014, 55(8): 1925-1929.
|
| [32] |
Metzeler KH,Walker A,Geyer S, et al.DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia[J]. Leukemia, 2012, 26(5): 1106-1107.
|
| [33] |
Popovici-Muller J,Shipps GW Jr,Rosner KE, et al.Pyrazolo[1, 5-a]pyrimidine-based inhibitors of HCV polymerase[J]. Bioorg Med Chem lett, 2009, 19(22): 6331-6336.
|
| [34] |
Rohle D,Popovici-Muller J,Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells[J]. Science, 2013, 340(6132): 626-630.
|
| [35] |
Turcan S,Fabius AW,Borodovsky A, et al.Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine[J]. Oncotarget, 2013, 4(10): 1729-1736.
|
| [36] |
Losman JA,Looper RE,Koivunen P, et al.(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible[J]. Science, 2013, 339(6127): 1621-1625.
|
| [37] |
Chaturvedi A,Araujo Cruz MM,Jyotsana N, et al.Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML[J]. Blood, 2013, 122(16): 2877-2887.
|
| [38] |
Wang F,Travins J,Delabarre B, et al.Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation[J]. Science, 2013, 340(6132): 622-626.
|
| [39] |
Emadi A,Jun SA,Tsukamoto T, et al.Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations[J]. Exp Hematol, 2014, 42(4): 247-251.
|